Company / Free Cash Flow
Janux Therapeutics, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$83.3M
FY2025
5-year range
-$83.3M / -$18.5M
FY2021-FY2025
Trend
-88.5%
vs FY2024
Sector context
#98 of 192
Health Care
What the data says
At -$83M, Janux Therapeutics, Inc.'s free cash flow ranks #98 of 192 in the Health Care sector. Declined from -$52M to -$83M over the past 2 years.
Based on SEC 10-K filings.
-$83M in FY2025.
Declined from -$52M to -$83M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#98 of 192 in Health CareTop 51% of 192This company -$83.3M Sector average $474.2M
▼
-117.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 88.5% year-over-year.
- Ranks #98 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$83.3M | -88.5% |
| FY2024 | -$44.2M | +15.7% |
| FY2023 | -$52.4M | -6.2% |
| FY2022 | -$49.4M | -167.5% |
| FY2021 | -$18.5M | -322.5% |
| FY2020 | -$4.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026